Publications

2024

Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia

Martin-Sanchez E, Blanco Fernández L, Kim PS, Bisht K, Wang H, Van de Velde H, Jelinek T, Simoes C, Prosper F, San-Miguel JF, Alfonso A, Bergua Burgues JM, Rodríguez-Veiga R, Vives S, Martínez-Cuadrón D, Montesinos P, Paiva B, Zabaleta A. Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia. Blood Adv. 2024 May 30:bloodadvances.2024013212. doi: https://doi.org/10.1182/bloodadvances.2024013212. Epub ahead of print. PMID: 38815228.

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors

Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, Venglar O, Muronova L, Broskevicova L, Nenarokov S, Bilek D, Popkova T, Plonkova H, Vrana J, Zidlik V, Hurnik P, Havel M, Hrdinka M, Chyra Z, Stracquadanio G, Simicek M, Hajek R. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024 Mar 16. doi: 10.1038/s41375-024-02206-w. Epub ahead of print. PMID: 38493239.

2023

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. J Clin Oncol. 2023 Jun 1;41(16):3019-3031. doi: 10.1200/JCO.22.01916. Epub 2023 Mar 17. PMID: 36930848.

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885. PMID: 36877894; PMCID: PMC10315622.

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics

Ogiya D, Chyra Z, Verselis SJ, O’Keefe M, Cobb J, Abiatari I, Talluri S, Sithara AA, Hideshima T, Chu MP, Hájek R, Dorfman DM, Pilarski LM, Anderson KC, Adamia S. Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. Blood Cancer J. 2023 Feb 3;13(1):23. doi: 10.1038/s41408-023-00791-0. PMID: 36737429; PMCID: PMC9898564.

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Fernandez RA, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2023 Jan 4;29(1):279-288. doi: 10.1158/1078-0432.CCR-22-1161. PMID: 36282272.

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

Haertle L, Buenache N, Cuesta Hernández HN, Simicek M, Snaurova R, Rapado I, Martinez N, López-Muñoz N, Sánchez-Pina JM, Munawar U, Han S, Ruiz-Heredia Y, Colmenares R, Gallardo M, Sanchez-Beato M, Piris MA, Samur MK, Munshi NC, Ayala R, Kortüm KM, Barrio S, Martínez-López J. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel). 2023 Jan 15;15(2):532. doi: 10.3390/cancers15020532. PMID: 36672481; PMCID: PMC9856285.

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

Ferrer-Curriu G, Soler-Botija C, Charvatova S, Motais B, Roura S, Galvez-Monton C, Monguió-Tortajada M, Iborra-Egea O, Emdin M, Lupón J, Aimo A, Bagó JR, Bayés-Genís A. Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. Biomed Pharmacother. 2023 Feb;158:114061. doi: 10.1016/j.biopha.2022.114061. Epub 2022 Dec 8. PMID: 36495661.

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment

Motais B, Charvátová S, Walek Z, Hájek R, Bagó JR. NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment. Cells. 2023 Nov 30;12(23):2748. doi: 10.3390/cells12232748. PMID: 38067177; PMCID: PMC10706019.

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Celichowski P, Turi M, Charvátová S, Radhakrishnan D, Feizi N, Chyra Z, Šimíček M, Jelínek T, Bago JR, Hájek R, Hrdinka M. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. J Transl Med. 2023 Mar 15;21(1):197. doi: 10.1186/s12967-023-04041-6. PMID: 36922828; PMCID: PMC10015723.

Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy

Venglar O, Kapustova V, Anilkumar Sithara A, Zihala D, Muronova L, Sevcikova T, Vrana J, Vdovin A, Radocha J, Krhovska P, Hrdinka M, Turjap M, Popkova T, Chyra Z, Broskevicova L, Simicek M, Koristek Z, Hajek R, Jelinek T. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. Br J Haematol. 2023 Oct 9. https://doi.org/10.1111/bjh.19141

Length-Dependent Translation Efficiency of ER-Destined Proteins

Sahinbegovic H, Vdovin A, Snaurova R, Durech M, Nezval J, Sobotka J, Hajek R, Jelinek T, Simicek M. Length-Dependent Translation Efficiency of ER-Destined Proteins. Curr Issues Mol Biol. 2023 Aug 14;45(8):6717-6727. doi: 10.3390/cimb45080425. PMID: 37623244; PMCID: PMC10453119.

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling

Turi M, Anilkumar Sithara A, Hofmanová L, Žihala D, Radhakrishnan D, Vdovin A, Knápková S, Ševčíková T, Chyra Z, Jelínek T, Šimíček M, Gullà A, Anderson KC, Hájek R, Hrdinka M. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling. Int J Mol Sci. 2023 Mar 15;24(6):5623. doi: 10.3390/ijms24065623. PMID: 36982699; PMCID: PMC10057398.

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease

Charvátová S, Motais B, Czapla J, Cichoń T, Smolarczyk R, Walek Z, Giebel S, Hájek R, Bagó JR. Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease. Cells. 2023 Jan 30;12(3):448. doi: 10.3390/cells12030448. PMID: 36766789; PMCID: PMC9914109.

2022

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 2022 Apr;36(4):1088-1101. doi: 10.1038/s41375-021-01475-z. Epub 2022 Jan 27. Erratum in: Leukemia. 2022 Jun;36(6):1700. PMID: 35082402; PMCID: PMC8979823.

Deubiquitinase OTUD1 Resolves Stalled Translation on polyA and Rare Codon Rich mRNAs

Snaurova R, Vdovin A, Durech M, Nezval J, Zihala D, Jelinek T, Hajek R, Simicek M. Deubiquitinase OTUD1 Resolves Stalled Translation on polyA and Rare Codon Rich mRNAs. Mol Cell Biol. 2022 Dec 15;42(12):e0026522. doi: 10.1128/mcb.00265-22. Epub 2022 Nov 29. PMID: 36445135; PMCID: PMC9753717.

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, Snaurova R, Radhakrishnan D, Turi M, Chyra Z, Popkova T, Venglar O, Hrdinka M, Hajek R, Simicek M. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun. 2022 Nov 10;13(1):6820. doi: 10.1038/s41467-022-34654-2. PMID: 36357400.

Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Alonso Fernandez R, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2022 Oct 25:CCR-22-1161. doi: 10.1158/1078-0432.CCR-22-1161. Epub ahead of print. PMID: 36282272.

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, Hrdinka M, Simicek M, Garcés JJ, Puig N, Cedena MT, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Mateos MV, San-Miguel JF, Paiva B, Pour L, Rihova L, Hajek R. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2022 Oct 31:JCO2201226. doi: 10.1200/JCO.22.01226. Epub ahead of print. PMID: 36315921.

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A. Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. Cells. 2022 Aug 14;11(16):2519. doi: 10.3390/cells11162519. PMID: 36010596; PMCID: PMC9406519.

Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma

R. Termini, D. Zihala, E. Terpos, A. Pérez-Montaña, T. Jelinek, M. Raab, N. Weinhold, E. K. Mai, A. L. Grab, J. Corre, F. Vergez, A. Sacco, M. Chiarini, V. Giustini, A. Tucci, S. Rodríguez, C. Moreno, C. Perez, C. Maia, E. Martin-Sanchez, C. Guerrero, C. Botta, J.J. Garcés, A. Lopez, L.E. Tamariz-Amador, F. Prósper, J. Bargay, M.E. Cabezudo, E.M. Ocio, R. Hájek, J. Martinez-Lopez, F. Solano, R. Iglesias, A. Paiva, C. Geraldes, H. Matos Silva, C. Gomez, F. De Arriba, H. Ludwig, A. Garcia-Guiñon, M. Casanova, A. Alegre, V. Cabañas, M. Sirvent, A. Oriol, J. De la Rubia, J.A. Hernández-Rivas, L. Palomera, M. Sarasa, P. Rios, N. Puig, M.V. Mateos, J. Flores-Montero, A. Orfao, H. Goldschmidt, H. Avet-Loiseau, A. M. Roccaro, J. F. San-Miguel, B. Paiva, 2022. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res; https://doi.org/10.1158/1078-0432.CCR-22-1594

2021

Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment

B. MotaisS. CharvátováZ. WalekM. Hrdinka, R. Smolarczyk, T. Cichoń, J. Czapla, S. Giebel, M. Šimíček, T. Jelínek, T. Ševčíková, J. Sobotka, Z. KořístekR. Hájek and J.R. Bagó, 2021. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. Cells; 10(5), 967; https://doi.org/10.3390/cells10050967 

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

T. JelinekT. SevcikovaD. Zihala, T. Popkova, V. KapustovaL. Broskevicova, L. Capkova, L. Rihova, R. Bezdekova, S. Sevcikova, V. Zidlik, M. Havel, H. Plonkova, A. Jungova, J. Minarik, M. Stork, L. Pour, P. Pavlicek, I. Spicka, V. Maisnar, J. Radocha, M. Simicek & R. Hajek , 2021. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia; https://doi.org/10.1038/s41375-021-01343-w;

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Zátopková M.Ševčíková T., Fanfani V., Chyra Z., Rihova L., Bezdekova R., Žihala D.Growková K.Filipova J.Černá L.Broskevičová L., Kryukov F., Minařík J., Smejkalová J., Maisnar V., Harvanová L., Pour L., Jungova A., Popková T.Bago J.R.Anilkumar Sithara A.Hrdinka M.Jelinek T.Šimíček M., Stracquadanio G., Hajek R.. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. Blood Adv. 2021 Sep 9. doi: 10.1182/bloodadvances.2020003876. Epub ahead of print. PMID: 34500459.

Scroll to Top